Immunotherapy can help the immune system fight cancer, but the heart can become an unintended target. This study found that the warning signal for heart inflammation was stronger in older patients across every treatment examined. Cancer is increasingly a disease of old age, and for several common reasons to begin immunotherapy, the typical patient is over 70.

But the people receiving these treatments in everyday care differ substantially from the people whose safety data established them: adults aged 75 or older typically made up fewer than 15 percent of trial participants. That creates a practical question: are older patients simply appearing more often in treatment reports because more of them receive these drugs, or is the heart-inflammation signal itself stronger with age?

The analysis was designed to map heart-related reports, describe the ages of affected patients, and compare the signal between younger and older groups across all six treatments. To look for an answer, the analysis searched a public record of suspected side effects, covering the period from the first approval of an immune treatment through March 2026.

It looked across six immune treatments and grouped heart-related reports into conditions such as heart inflammation, rhythm problems, heart failure, cardiac arrest, and heart attack. Here is the everyday comparison: a disproportionality signal flags an unusual reporting pattern, but it does not directly measure the chance that any one person will experience the event.

Across the full reporting system, all six treatments showed highly elevated signals for heart inflammation, meaning myocarditis appeared disproportionately often in reports for each treatment. For the treatments considered together, the combined signal was well above the usual threshold used to flag a possible safety concern.

The age pattern was striking. Two-thirds of the heart-inflammation reports involved patients aged 65 or older, and more than a quarter involved patients aged 75 or older. Those shares were higher than the representation of these age groups in the major trials for each treatment.

The reports therefore came disproportionately from the same older group that the trials studied less. The age mix shifts noticeably between treatments: some reports span all age groups, while others are concentrated among the oldest patients, though the smallest group is least certain.

Then came the central finding: the reporting signal was higher in patients aged 65 or older than in younger patients for all six treatments. For the five treatments with enough reports for a steadier comparison, the older-group signal was between 1.6 and 3.1 times the younger-group signal.

That pattern appeared across treatments rather than belonging to just one drug. But this does not mean that older age has been proven to cause more heart inflammation. The records do not show how many people in each age group received each treatment, how long they received it, or what other illnesses and treatment details they had.

So these are age-linked reporting signals, not the true rate of illness or a direct measure of personal risk. The authors say the pattern needs confirmation in studies that can compare patients with known treatment exposure. Taken together, the reports point to two disadvantages for older adults: they were underrepresented in the trials that established safety, while the heart-inflammation signal was amplified in the group those trials studied least.

The practical next step is to bring heart checks more fully into care for older people receiving immunotherapy, with attention to age, the patient’s wider health, and communication with caregivers. The finding is a warning signal, not proof of a higher true risk: older adults are both underrepresented in the trials behind these treatments and prominent in reports of heart inflammation.

That makes closer heart monitoring and clearer conversations especially important.